Piper Sandler Forecasts Strong Price Appreciation for Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) had its target price raised by equities researchers at Piper Sandler from $36.00 to $40.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the spec…

Read Full Article →